Your session is about to expire
← Back to Search
PEA plus Treatment as Usual (TAU) for Depression, Bipolar Disorder
Study Summary
This trial aims to determine if a medication called PEA can effectively treat bipolar depression. The study will also look at how the body's natural cannabinoids and cytokine levels are related to the response to antidepress
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the combination of PEA and Treatment as Usual (TAU) received official approval from the FDA?
"Based on our assessment, the safety of PEA plus Treatment as Usual (TAU) is rated at 2. This score reflects that while there is some existing data supporting its safety, no evidence has been found yet to support its efficacy in this Phase 2 trial."
Who is eligible to participate in this clinical trial?
"To be considered eligible for this clinical trial, individuals must have a diagnosis of depression or bipolar disorder and fall within the age range of 18 to 70. Approximately 50 participants will be accepted into the study."
Can minors under the age of 18 participate in this particular medical study?
"As outlined in the trial's eligibility criteria, individuals aged 18 to 70 years are eligible for participation."
What is the current number of individuals enrolled in this clinical trial?
"Indeed, according to the information available on clinicaltrials.gov, this study is actively seeking eligible candidates. The trial was initially posted on May 17th, 2023 and recently updated on January 19th, 2024. It plans to enroll a total of 50 participants at one designated location."
Are participants still being actively enrolled in this research study at the moment?
"As per the available information on clinicaltrials.gov, this trial is presently in the process of actively recruiting eligible participants. The initial posting of this study was made on May 17th, 2023 and it underwent its most recent update on January 19th, 2024."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger